Also, studies with RA patients who do not have diabetes could show whether IL-1 inhibitor therapy can prevent prediabetes and T2DM in specific patient risk groups, such as those who have RA and obesity or metabolic syndrome [100]. Here, IL1A is linked to obesity disorder.